Navigation Links
Metabolic syndrome biomarkers predict lung function impairment after exposure to WTC dust
Date:11/17/2011

Metabolic syndrome biomarkers predict subsequent decline in lung function after particulate exposure, according to new research involving rescue personnel exposed to World Trade Center (WTC) dust.

In a nested case-control study of 327 non-smoking FDNY 9/11 rescue workers, metabolic syndrome biomarkers measured within six months of exposure to WTC dust predicted decline of forced expiratory volume in one second (FEV1) over the next six years.

"Study participants with dyslipidemia, elevated heart rate or elevated leptin levels had a significantly increased risk of developing abnormal lung function during follow-up," said Anna Nolan, MD, MS, assistant professor of Medicine and Environmental Medicine at NYU Langone Medical Center. "In contrast, elevated amylin levels reduced the risk of developing abnormal FEV1 levels."

The findings were published online ahead of print publication in the American Thoracic Society's American Journal of Respiratory and Critical Care Medicine.

This case-control study was nested within a larger longitudinally followed cohort. All subjects had normal lung function prior to 9/11. Cases (n = 109) were defined as having FEV1 values below the lower limit of normal at follow-up, while controls (n = 218) were defined as having FEV1 at or above the lower limit of normal. Biomarkers were available for 71 cases and 166 controls. Lung function in cases continually declined in the median 28 months between baseline and follow-up examinations, while lung function improved in controls.

In a model adjusting for age, race, body mass index and WTC arrival time, dyslipidemia (triglycerides≥150mg/dL and HDL<40mg/dL) increased the odds of being a case three-fold, elevated heart rate (≥66 bpm) increased the odds more than two-fold, and elevated leptin (≥10,300 pg/mL) increased the odds three-fold. Elevated amylin levels (≥116 pg/mL) decreased the odds of being a case by 84 percent. "This is the first report in humans showing an association between amylin and lung function," Dr. Nolan said. "There are amylin receptors in the lungs, and amylin has been shown to reduce leptin resistance. The protection offered by amylin in this study may have been mediated by these effects."

"These findings suggest that systemic inflammation, a hallmark of the metabolic syndrome, may play a role in promoting lung function impairment in patients with particulate exposure," Dr. Nolan said. "Given the high prevalence of the metabolic syndrome in industrialized nations and the rising incidence in developing nations with high ambient particulate levels, the relationship between these disorders is of considerable importance."

The study had a few limitations. Use of a single cohort of rescue workers limits extrapolation of these results to other cohorts. There was no unexposed control group in this study, so replication of these findings in populations with and without exposure to particulate matter is needed. Finally, other possible causes of lung dysfunction were not explored.

"Our findings in WTC rescue workers highlight the importance of conducting rapid medical monitoring and sample banking following a disaster," said Dr. Nolan. "If we can identify individuals at greater risk of developing lung function impairment, we can initiate appropriate interventions earlier."


'/>"/>

Contact: Nathaniel Dunford
ndunford@thoracic.org
212-315-8620
American Thoracic Society
Source:Eurekalert

Related medicine news :

1. Mild-mannered metabolic helper rushes to fight invading viruses, researchers report
2. Flies offer insight into human metabolic disease
3. Vitamin D Deficiency Linked to Diabetes, Metabolic Syndrome in Studies
4. Metabolic syndrome in living kidney donors worsens function of remaining kidney
5. Low vitamin D linked to the metabolic syndrome in elderly people
6. LSUHSC study finds early predictors of metabolic syndrome in healthy 7-9 year-olds
7. UC San Diego researchers find cause of metabolic disease -- and possible cure
8. Metabolic status before pregnancy predicts subsequent gestational diabetes
9. Moderate alcohol consumption lowers the risk of metabolic diseases
10. Loud snoring and insomnia symptoms predict the development of the metabolic syndrome
11. Vitamins C and E linked to metabolic syndrome in low-income Ecuadorians
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2016)... KING OF PRUSSIA, PA and LONDON, UK (PRWEB) , ... May ... ... continues to earn accolades for his success in changing the way the pharmaceutical industry ... Power 100 list of the world’s most influential people in pharma, and he was ...
(Date:5/6/2016)... Chandler, AZ (PRWEB) , ... May 06, 2016 ... ... No Greater Odds, are scheduled to provide a unique keynote address at the ... documentary follows the inspirational stories of five community college students. Their stories—of complicated ...
(Date:5/6/2016)... ... ... A wide variety of national pet product manufacturers, companies and brands will gather for one ... 18 from noon to 8 p.m. at New York City’s Roger Smith Hotel. The event ... garden, outdoor and safety pet products in today’s marketplace. , Petrend Event showcases ...
(Date:5/6/2016)... Jupiter, FL (PRWEB) , ... May 06, 2016 ... ... it will feature AsedaSciences® in an upcoming episode, airing third quarter 2016, via ... with the vision of becoming a leader in optimized drug discovery through innovative ...
(Date:5/6/2016)... Pass, OR (PRWEB) , ... May 06, 2016 , ... ... eyes. In other seasons, when the weather is too cold, dry or hot, water ... the eyes can actually absorb moisture from the surrounding air. There’s only one problem, ...
Breaking Medicine News(10 mins):
(Date:5/4/2016)... ZIONA, Israel , May 4, ... TASE: BVXV) announced today that BiondVax,s CEO, Dr. Ron ... conference in New York City . ... at 10:30am at Pioneers 2016, a conference presented by ... York Palace Hotel. The BiondVax presentation that Dr. ...
(Date:5/4/2016)... May 4, 2016 Yissum ... announced today that it had signed an exclusive ... , developer of novel protein degradation and immunomodulatory drugs ... commercialization of drug candidates representing first-in-class therapy for hematologic ... not disclosed. The novel technology was developed ...
(Date:5/4/2016)... , May 4, 2016 ... completion of an alternative public offering (APO). This was ... operating company, Valeritas, Inc. and a private placement of ... at $5.00 per share. Under the terms ... 3, 2016, Valeritas Holdings, Inc. will trade on the ...
Breaking Medicine Technology: